Literature DB >> 12850213

The role of voltage-gated sodium channels in neuropathic pain.

Josephine Lai1, John C Hunter, Frank Porreca.   

Abstract

Use-dependent inhibitors of voltage-gated sodium channels (VGSC) are important therapeutic tools for chronic pain management, but are limited by possible severe side effects. Recent studies have provided much new information on the function of several voltage-gated sodium channels that are predominantly expressed in peripheral sensory neurons, and on their possible link to pathological pain states arising from injuries to the sensory nerve. The use of antisense oligonucleotides to target specific channel subtypes shows that the functional localization of the channel subtype Na(V)1.8 after nerve injury is essential for persistent pain states. The putative roles of Na(V)1.3 and Na(V)1.9 in neuropathic pain are also discussed. These studies may form a basis for developing inhibitors to target specific channel subtype(s) for use in chronic pain treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850213     DOI: 10.1016/s0959-4388(03)00074-6

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  32 in total

1.  Hyperpolarized shifts in the voltage dependence of fast inactivation of Nav1.4 and Nav1.5 in a rat model of critical illness myopathy.

Authors:  Gregory N Filatov; Mark M Rich
Journal:  J Physiol       Date:  2004-07-14       Impact factor: 5.182

Review 2.  Voltage-gated Na+ channels: multiplicity of expression, plasticity, functional implications and pathophysiological aspects.

Authors:  J K J Diss; S P Fraser; M B A Djamgoz
Journal:  Eur Biophys J       Date:  2004-02-12       Impact factor: 1.733

3.  The tetrodotoxin-resistant Na+ channel Na (v)1.8 reduces the potency of local anesthetics in blocking C-fiber nociceptors.

Authors:  Katrin Kistner; Katharina Zimmermann; Corina Ehnert; Peter W Reeh; Andreas Leffler
Journal:  Pflugers Arch       Date:  2010-02-23       Impact factor: 3.657

4.  [New substances and applications for postoperative pain therapy].

Authors:  E M Pogatzki-Zahn; P K Zahn
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

5.  [Types of topical treatment for peripheral neuropathic pain : Mechanism of action and indications].

Authors:  R Baron; F Mahn
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

Review 6.  Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets.

Authors:  P Boadas-Vaello; S Castany; J Homs; B Álvarez-Pérez; M Deulofeu; E Verdú
Journal:  Spinal Cord       Date:  2016-01-12       Impact factor: 2.772

7.  Genetic architecture of a feeding adaptation: garter snake (Thamnophis) resistance to tetrodotoxin bearing prey.

Authors:  Chris R Feldman; Edmund D Brodie; Edmund D Brodie; Michael E Pfrender
Journal:  Proc Biol Sci       Date:  2010-06-03       Impact factor: 5.349

8.  Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons.

Authors:  Munmun Chattopadhyay; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2011-04-12       Impact factor: 3.931

Review 9.  Analgesic therapy for major spine surgery.

Authors:  Varun Puvanesarajah; Jason A Liauw; Sheng-fu Lo; Ioan A Lina; Timothy F Witham; Allan Gottschalk
Journal:  Neurosurg Rev       Date:  2015-02-14       Impact factor: 3.042

Review 10.  Challenges in the development of novel treatment strategies for neuropathic pain.

Authors:  Michael H Ossipov; Frank Porreca
Journal:  NeuroRx       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.